OncoMatch/Clinical Trials/NCT06018896
Vitamin C to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
Is NCT06018896 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Ascorbate for metastatic pancreatic cancer.
Treatment: Ascorbate — The purpose of this study is to evaluate the efficacy of vitamin C in improving the quality of life for metastatic pancreatic cancer patients who are resistant to chemotherapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Required: Stage IV
Metastatic disease required
Histologically or cytologically confirmed metastatic pancreas adenocarcinoma. Presence of at least of one measurable lesion in agreement to Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: cytotoxic chemotherapy
Tumor progression after two lines of chemotherapy.
Lab requirements
Kidney function
Renal insufficiency or dialysis [excluded]
Adequate organ performance based on laboratory blood tests. Renal insufficiency or dialysis [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06018896 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received cytotoxic chemotherapy.
What disease stage is eligible?
Stage IV is required (metastatic disease required).
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages